Breast Cancer Prognostic Assay
Pre-clinical- Indications
- Breast cancer
Company intelligence / Profile preview
Xceed Molecular
Toronto, Ontario, Canadaxceedmolecular.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The company was developing a Breast Cancer Prognostic Assay designed to predict risk of recurrence for breast cancer patients, with plans for commercial launch in 2011 (at the time of acquisition)
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Gene expression analysisDNA and RNA biomarkers
- Industry
- Molecular Diagnostics
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
University of Florida (Strategic Collaborator Program)
Beyond the preview
Go deeper on Xceed Molecular.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xceed Molecular.